Literature DB >> 11740733

Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant.

E Josefsson1, O Hartford, L O'Brien, J M Patti, T Foster.   

Abstract

The importance of the fibrinogen-binding adhesin clumping factor A (ClfA) in the pathogenesis of Staphylococcus aureus septic arthritis was examined in an animal model. The protective effect of active and passive immunization with ClfA also was investigated in S. aureus infection models. The severity of arthritis was markedly reduced in mice challenged intravenously with a clfA mutant, compared with mice infected with the wild-type strain. Mice immunized with recombinant ClfA and challenged with S. aureus developed less-severe arthritis than did mice immunized with a control antigen. Passive immunization of mice with rat and rabbit anti-ClfA antibodies protected against S. aureus arthritis and sepsis-induced death, indicating that the protection by active immunization is antibody mediated. Taken together, these data strongly suggest that ClfA is a crucial virulence determinant for septic arthritis and an excellent target for the generation of immune therapies directed against S. aureus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740733     DOI: 10.1086/324430

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  109 in total

Review 1.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 2.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Authors:  Rebecca A Brady; Christopher P Mocca; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

4.  New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans.

Authors:  Walid F Elkhatib; Pamela S Hair; Julius O Nyalwidhe; Kenji M Cunnion
Journal:  J Med Microbiol       Date:  2015-04       Impact factor: 2.472

Review 5.  Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus.

Authors:  Timothy J Foster; Joan A Geoghegan; Vannakambadi K Ganesh; Magnus Höök
Journal:  Nat Rev Microbiol       Date:  2014-01       Impact factor: 60.633

6.  Immunorelevant proteins for the diagnosis of bovine staphylococcal mastitis.

Authors:  M H Fabres-Klein; R C Klein; S O De Paula; A O B Ribon
Journal:  World J Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.312

7.  Vaccine assembly from surface proteins of Staphylococcus aureus.

Authors:  Yukiko K Stranger-Jones; Taeok Bae; Olaf Schneewind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

8.  Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.

Authors:  Agnieszka Dryla; Sonja Prustomersky; Dieter Gelbmann; Markus Hanner; Edith Bettinger; Béla Kocsis; Tamás Kustos; Tamás Henics; Andreas Meinke; Eszter Nagy
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus.

Authors:  Vilasack Thammavongsa; Sabine Rauch; Hwan Keun Kim; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2014-12-06       Impact factor: 3.641

10.  Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis.

Authors:  Tiago Rafael Veloso; Aziz Chaouch; Thierry Roger; Marlyse Giddey; Jacques Vouillamoz; Paul Majcherczyk; Yok-Ai Que; Valentin Rousson; Philippe Moreillon; José Manuel Entenza
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.